Biomarkers identified for Avastin resistance in cancer patients

Avastin, Genentech/Roche's trade name for bevacizumab, is frequently used to treat various cancers because it blocks the growth of new blood vessels. But all too frequently, some patients develop a resistance to Avastin. Circadian Technologies has found what it says are two biomarkers that indicate which colorectal cancer patients might be resistant to Avastin. VEGF-C and VEGF-D appear to play roles in chemotherapy resistance. More studies are planned. Release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.